Denali Therapeutics startet Phase-1-Studie mit DNL952 zur Behandlung von Pompe-Krankheit

Reuters02-06

Denali <a href="https://laohu8.com/S/LENZ">Therapeutics</a> startet Phase-1-Studie mit DNL952 zur Behandlung von Pompe-Krankheit

Denali Therapeutics Inc. hat auf dem 22. Annual WORLDSymposium Daten aus klinischen Programmen zu Hunter-Syndrom (MPS II), Sanfilippo-Syndrom Typ A (MPS IIIA) und Pompe-Krankheit präsentiert. Im Rahmen der Veranstaltung wurden neue Ergebnisse zur Wirksamkeit und Sicherheit von Tividenofusp alfa (DNL310) bei Hunter-Syndrom sowie erste Daten zur Behandlung mit DNL126 bei Sanfilippo-Syndrom Typ A vorgestellt. Ebenfalls wurde das Studiendesign und präklinische Daten für DNL952 (ETV:GAA) zur Behandlung der Pompe-Krankheit präsentiert. Denali bereitet sich zudem auf die mögliche Markteinführung von Tividenofusp alfa vor, deren PDUFA-Entscheidung für den 5. April 2026 erwartet wird.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9649787-en) on February 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2609585203?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 03:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609585203","market":"us","top_or_hot":-1,"title":"Denali Therapeutics startet Phase-1-Studie mit DNL952 zur Behandlung von Pompe-Krankheit","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> startet Phase-1-Studie mit DNL952 zur Behandlung von Pompe-Krankheit\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNLI\">Denali Therapeutics Inc.</a> hat auf dem 22. Annual WORLDSymposium Daten aus klinischen Programmen zu Hunter-Syndrom (MPS II), Sanfilippo-Syndrom Typ A (MPS IIIA) und Pompe-Krankheit präsentiert. Im Rahmen der Veranstaltung wurden neue Ergebnisse zur Wirksamkeit und Sicherheit von Tividenofusp alfa (DNL310) bei Hunter-Syndrom sowie erste Daten zur Behandlung mit DNL126 bei Sanfilippo-Syndrom Typ A vorgestellt. Ebenfalls wurde das Studiendesign und präklinische Daten für DNL952 (ETV:GAA) zur Behandlung der Pompe-Krankheit präsentiert. Denali bereitet sich zudem auf die mögliche Markteinführung von Tividenofusp alfa vor, deren PDUFA-Entscheidung für den 5. April 2026 erwartet wird.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9649787-en) on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Denali Therapeutics startet Phase-1-Studie mit DNL952 zur Behandlung von Pompe-Krankheit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDenali Therapeutics startet Phase-1-Studie mit DNL952 zur Behandlung von Pompe-Krankheit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-06 03:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> startet Phase-1-Studie mit DNL952 zur Behandlung von Pompe-Krankheit\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNLI\">Denali Therapeutics Inc.</a> hat auf dem 22. Annual WORLDSymposium Daten aus klinischen Programmen zu Hunter-Syndrom (MPS II), Sanfilippo-Syndrom Typ A (MPS IIIA) und Pompe-Krankheit präsentiert. Im Rahmen der Veranstaltung wurden neue Ergebnisse zur Wirksamkeit und Sicherheit von Tividenofusp alfa (DNL310) bei Hunter-Syndrom sowie erste Daten zur Behandlung mit DNL126 bei Sanfilippo-Syndrom Typ A vorgestellt. Ebenfalls wurde das Studiendesign und präklinische Daten für DNL952 (ETV:GAA) zur Behandlung der Pompe-Krankheit präsentiert. Denali bereitet sich zudem auf die mögliche Markteinführung von Tividenofusp alfa vor, deren PDUFA-Entscheidung für den 5. April 2026 erwartet wird.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9649787-en) on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DNLI","symbol_name":"Denali Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL8g3Q24:1","article_id":"2609585203","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609585203","pubTimestamp":1770318028,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Denali Therapeutics Inc. hat auf dem 22. Annual WORLDSymposium Daten aus klinischen Programmen zu Hunter-Syndrom , Sanfilippo-Syndrom Typ A  und Pompe-Krankheit prsentiert. Im Rahmen der Veranstaltung wurden neue Ergebnisse zur Wirksamkeit und Sicherheit von Tividenofusp alfa  bei Hunter-Syndrom sowie erste Daten zur Behandlung mit DNL126 bei Sanfilippo-Syndrom Typ A vorgestellt. Ebenfalls wurde das Studiendesign und prklinische Daten für DNL952  zur Behandlung der Pompe-Krankheit prsentiert. Denali bereitet sich zudem auf die mgliche Markteinführung von Tividenofusp alfa vor, deren PDUFA-Entscheidung für den 5. April 2026 erwartet wird.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original cont","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DNLI":"Denali Therapeutics Inc.","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","BK4139":"生物科技","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4535":"淡马锡持仓","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","BK4548":"巴美列捷福持仓","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Denali Therapeutics启动DNL952治疗庞贝病的1期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"DNLI":0.9},"content_text":"Denali Therapeutics startet Phase-1-Studie mit DNL952 zur Behandlung von Pompe-Krankheit\n    \n\nDenali Therapeutics Inc. hat auf dem 22. Annual WORLDSymposium Daten aus klinischen Programmen zu Hunter-Syndrom (MPS II), Sanfilippo-Syndrom Typ A (MPS IIIA) und Pompe-Krankheit präsentiert. Im Rahmen der Veranstaltung wurden neue Ergebnisse zur Wirksamkeit und Sicherheit von Tividenofusp alfa (DNL310) bei Hunter-Syndrom sowie erste Daten zur Behandlung mit DNL126 bei Sanfilippo-Syndrom Typ A vorgestellt. Ebenfalls wurde das Studiendesign und präklinische Daten für DNL952 (ETV:GAA) zur Behandlung der Pompe-Krankheit präsentiert. Denali bereitet sich zudem auf die mögliche Markteinführung von Tividenofusp alfa vor, deren PDUFA-Entscheidung für den 5. April 2026 erwartet wird.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9649787-en) on February 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609585203","isCrawlerRequest":true}